<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476879</url>
  </required_header>
  <id_info>
    <org_study_id>090600-deleted</org_study_id>
    <nct_id>NCT00476879</nct_id>
  </id_info>
  <brief_title>Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content</brief_title>
  <official_title>Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of growth hormone during fasting in
      healthy lean men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During fasting the human body is known to metabolize relatively large amounts of fat, in the
      expense of proteins and glucose. Partly this shift in metabolism is caused by increasing GH
      secretion, but exactly how growth hormone exerts these effects remains to be further
      investigated.

      10 healthy lean young men are studied at 4 different occasions in a randomized single-blinded
      cross-over study. 1: after 12 hours of fasting + GH bolus, 2: after 36 hours of fasting + GH
      bolus, 3: after 36 hours + saline, 4: after 36 hours of fasting + Somavert.

      Aim:

        -  to study the signal transduction in muscle and fat tissue

        -  to study the metabolism during fasting

        -  to study the intrahepatic fat content using magnetic resonance techniques
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in intrahepatic lipid content</measure>
    <time_frame>12 and 36 hours of fasting. respectively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in intracellular signaling during fasting</measure>
    <time_frame>36 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in respiratory quotient</measure>
    <time_frame>36 hours of fasting</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>metabolism</measure>
    <time_frame>36 hours of fasting</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>36 hours of fasting</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>forearm metabolism</measure>
    <time_frame>36 hours of fasting</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in FFA</measure>
    <time_frame>36 hours of fasting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in grelin</measure>
    <time_frame>36 hours of fasting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in leptin, adiponektin, cortisol, catecholamine, glucagon, carbamide, palmitate</measure>
    <time_frame>36 hours of fasting</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Metabolism</condition>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 hours of fasting and a GH bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>36 hours of fasting and a GH bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>36 hours of fasting and Pegvisomant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>36 hours of fasting and NaCl injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin and pegvisomant</intervention_name>
    <description>Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male

          -  healthy

          -  age 20 - 40 years of age

          -  BMI 20 -25

        Exclusion Criteria:

          -  uses any medication

          -  drinks more than 21 units of alcohol per

          -  is claustrophobic

          -  carries any magnetic devices
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise Moller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical department M, Aarhus Sygehus, Norrebrogade 44, 8000 Aarhus, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical department M, Arhus Sygehus, Region midtjylland</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2007</study_first_submitted>
  <study_first_submitted_qc>May 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2007</study_first_posted>
  <last_update_submitted>August 11, 2008</last_update_submitted>
  <last_update_submitted_qc>August 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jens Otto Lunde Jorgensen</name_title>
    <organization>Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus</organization>
  </responsible_party>
  <keyword>Growth hormone</keyword>
  <keyword>Fasting</keyword>
  <keyword>Signaltransduction</keyword>
  <keyword>fatty liver</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>forearm model</keyword>
  <keyword>protein metabolism</keyword>
  <keyword>respiratory quotient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

